Seminars in Radiation Oncology
Volume 17, Issue 3 , Pages 158-168 , July 2007

Cutaneous Lymphomas

  • Benjamin D. Smith, MD

      Affiliations

    • United States Air Force, Wilford Hall Medical Center, Lackland AFB, TX.
    • ,
  • Lynn D. Wilson, MD, MPH

      Affiliations

    • Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT.
    • Corresponding Author InformationAddress reprint requests to Lynn D. Wilson, MD, MPH, Department of Therapeutic Radiology, Yale University School of Medicine, HRT 132, 333 Cedar Street, New Haven, CT 06520.

References 

  1. Groves FD, Linet MS, Travis LB, et al. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240–1251
  2. Smith BD, Smith GL, Cooper DL, et al. The cutaneous B-cell lymphoma prognostic index: A novel prognostic index derived from a population-based registry. J Clin Oncol. 2005;23:3390–3395
  3. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354–371
  4. World Health Organization. Classification of Tumors. In:  Jaffe ES,  Harris NL,  Stein H editor. Pathology and Genetics of Tumours of Hematopoietic and Lympoid Tissues. Lyon, France: IARC Press; 2001;
  5. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785
  6. Fung MA, Murphy MJ, Hoss DM, et al. Practical evaluation and management of cutaneous lymphoma. J Am Acad Dermatol. 2002;46:325–357
  7. Ashton-Key M, Diss TC, Du MQ, et al. The value of the polymerase chain reaction in the diagnosis of cutaneous T-cell infiltrates. Am J Surg Pathol. 1997;21:743–747
  8. Dadej K, Gaboury L, Lamarre L, et al. The value of clonality in the diagnosis and follow-up of patients with cutaneous T-cell infiltrates. Diagn Mol Pathol. 2001;10:78–88
  9. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Handbook. (ed 6). New York, NY: Springer; 2002;
  10. Kim YH, Jensen RA, Watanabe GL, et al. Clinical stage IA (limited patch and plaque) mycosis fungoides (A long- term outcome analysis). Arch Dermatol. 1996;132:1309–1313
  11. Kim YH, Hoppe RT. Mycosis fungoides and the Sezary syndrome. Semin Oncol. 1999;26:276–289
  12. de Coninck EC, Kim YH, Varghese A, et al. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol. 2001;19:779–784
  13. Kim YH, Bishop K, Varghese A, et al. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol. 1995;131:1003–1008
  14. Diamandidou E, Colome M, Fayad L, et al. Prognostic factor analysis in mycosis fungoides/Sezary syndrome. J Am Acad Dermatol. 1999;40:914–924
  15. Wasik MA, Vonderheid EC, Bigler RD, et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma (Clinical and prognostic implications). Arch Dermatol. 1996;132:42–47
  16. Delfau-Larue MH, Dalac S, Lepage E, et al. Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides. Blood. 1998;92:3376–3380
  17. Guitart J, Camisa C, Ehrlich M, et al. Long-term implications of T-cell receptor gene rearrangement analysis by Southern blot in patients with cutaneous T-cell lymphoma. J Am Acad Dermatol. 2003;48:775–779
  18. Beylot-Barry M, Sibaud V, Thiebaut R, et al. Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas. J Invest Dermatol. 2001;117:920–926
  19. Bakels V, Van Oostveen JW, Geerts ML, et al. Diagnostic and prognostic significance of clonal T-cell receptor beta gene rearrangements in lymph nodes of patients with mycosis fungoides. J Pathol. 1993;170:249–255
  20. Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: Report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002;46:95–106
  21. Hoppe RT. Mycosis fungoides: Radiation therapy. Dermatol Ther. 2003;16:347–354
  22. Cotter GW, Baglan RJ, Wasserman TH, et al. Palliative radiation treatment of cutaneous mycosis fungoides—A dose response. Int J Radiat Oncol Biol Phys. 1983;9:1477–1480
  23. Wilson LD, Kacinski BM, Jones GW. Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (Mycosis Fungoides). Int J Radiat Oncol Biol Phys. 1998;40:109–115
  24. Kim JH, Nisce LZ, D’Anglo GJ. Dose-time fractionation study in patients with mycosis fungoides and lymphoma cutis. Radiology. 1976;119:439–442
  25. Micaily B, Miyamoto C, Kantor G, et al. Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys. 1998;42:361–364
  26. Wong R, Jones G, Farrar N, et al. Local superficial radiotherapy (LSRT) for newly diagnosed stage IA patch-plaque mycosis fungoides (MF) with only one, two, or three presenting lesions. Int J Radiat Oncol Biol Phys. 2003;57(suppl 1):S289–S290
  27. Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol. 2002;47:364–370
  28. Hoppe RT, Fuks Z, Bagshaw MA. The rationale for curative radiotherapy in mycosis fungoides. Int J Radiat Oncol Biol Phys. 1977;2:843–851
  29. Jones GW, Tadros A, Hodson DI, et al. Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 GY. Int J Radiat Oncol Biol Phys. 1994;28:839–845
  30. Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9:1057–1076
  31. Chen Z, Agostinelli AG, Wilson LD, et al. Matching the dosimetry characteristics of a dual-field Stanford technique to a customized single-field Stanford technique for total skin electron therapy. Int J Radiat Oncol Biol Phys. 2004;59:872–885
  32. Gamble LM, Farrell TJ, Jones GW, et al. Composite depth dose measurement for total skin electron (TSE) treatments using radiochromic film. Phys Med Biol. 2003;48:891–898
  33. Anacak Y, Arican Z, Bar-Deroma R, et al. Total skin electron irradiation: Evaluation of dose uniformity throughout the skin surface. Med Dosim. 2003;28:31–34
  34. Jones G, Wilson LD, Fox-Goguen L. Total skin electron beam radiotherapy for patients who have mycosis fungoides. Hematol Oncol Clin North Am. 2003;17:1421–1434
  35. Quiros PA, Kacinski BM, Wilson LD. Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T-cell lymphoma treated with total skin electron beam radiation therapy. Cancer. 1996;77:1912–1917
  36. Chinn DM, Chow S, Kim YH, et al. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys. 1999;43:951–958
  37. Jones GW, Rosenthal D, Wilson LD. Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome). Cancer. 1999;85:1985–1995
  38. Wilson LD, Quiros PA, Kolenik SA, et al. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996;35:69–73
  39. Becker M, Hoppe RT, Knox SJ. Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys. 1995;32:1445–1449
  40. Quiros PA, Jones GW, Kacinski BM, et al. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys. 1997;38:1027–1035
  41. Wilson LD, Jones GW, Kim D, et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol. 2000;43:54–60
  42. Rook AH, Kuzel TM, Olsen EA. Cytokine therapy of cutaneous T-cell lymphoma: Interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am. 2003;17:1435–1448
  43. Price NM. Electron beam therapy (Its effect on eccrine gland function in mycosis fungoides patients). Arch Dermatol. 1979;115:1068–1070
  44. Desai KR, Pezner RD, Lipsett JA, et al. Total skin electron irradiation for mycosis fungoides: Relationship between acute toxicities and measured dose at different anatomic sites. Int J Radiat Oncol Biol Phys. 1988;15:641–645
  45. Licata AG, Wilson LD, Braverman IM, et al. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma (The influence of additional therapy after total skin electron beam radiation). Arch Dermatol. 1995;131:432–435
  46. Smith BD, Wilson LD: Management of mycosis fungoides: Part 2. Treatment. Oncology (Huntingt) 17:1419-1428; discussion 1430, 1433, 2003
  47. Siegel RS, Pandolfino T, Guitart J, et al. Primary cutaneous T-cell lymphoma: Review and current concepts. J Clin Oncol. 2000;18:2908–2925
  48. Liu HL, Hoppe RT, Kohler S, et al. CD30+ cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49:1049–1058
  49. Cabanillas F, Armitage J, Pugh WC, et al. Lymphomatoid papulosis: A T-cell dyscrasia with a propensity to transform into malignant lymphoma. Ann Intern Med. 1995;122:210–217
  50. Beljaards RC, Willemze R. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol. 1992;126:596–602
  51. Smith BD, Glusac EJ, McNiff JM, et al. Primary cutaneous B-cell lymphoma treated with radiotherapy: A comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol. 2004;22:634–639
  52. Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B-cell lymphoma: The Italian Study Group for Cutaneous Lymphomas. J Clin Oncol. 2006;24:1376–1382
  53. Grange F, Bekkenk MW, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: A European multicenter study. J Clin Oncol. 2001;19:3602–3610
  54. Grange F, Petrella T, Beylot-Barry M, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood. 2004;103:3662–3668
  55. Sundram U, Kim Y, Mraz-Gernhard S, et al. Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: A tissue microarray study. J Cutan Pathol. 2005;32:227–234
  56. Eich HT, Eich D, Micke O, et al. Long-term efficacy, curative potential, and prognostic factors of radiotherapy in primary cutaneous B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2003;55:899–906
  57. Santucci M, Pimpinelli N, Arganini L. Primary cutaneous B-cell lymphoma: A unique type of low-grade lymphoma (Clinicopathologic and immunologic study of 83 cases). Cancer. 1991;67:2311–2326
  58. Piccinno R, Caccialanza M, Berti E. Dermatologic radiotherapy of primary cutaneous follicle center cell lymphoma. Eur J Dermatol. 2003;13:49–52
  59. Rijlaarsdam JU, Toonstra J, Meijer OW, et al. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: A clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy. J Clin Oncol. 1996;14:549–555
  60. Kirova YM, Piedbois Y, Le Bourgeois JP. Radiotherapy in the management of cutaneous B-cell lymphoma (Our experience in 25 cases). Radiother Oncol. 1999;52:15–18

PII: S1053-4296(07)00012-4

doi: 10.1016/j.semradonc.2007.02.001

Seminars in Radiation Oncology
Volume 17, Issue 3 , Pages 158-168 , July 2007

Article Tools

* Image Usage & Resolution